The Novel Treatment For Reproductive Disorders- Kisspeptin

The KISS1 gene encodes the novel treatment for reproductive disorders, Kisspeptin, a peptide of just 54 amino acids created by cleaving a longer peptide of 145 amino acids.

Researchers may stifle cancer-causing aberrant cell proliferation, and one can avoid illnesses like melanomas and breast carcinomas thanks to a gene called KISS1.

Kisspeptin was first identified as a metastasis suppressor, but its unique expression profile has since shown its favorable effects on the hypothalamus, pituitary gland, and, thus, the reproductive system.

History of Kisspeptin

During the middle of the 1990s, human chromosome 6 was introduced into a cancer cell, and experts discovered that this chromosome (later dubbed the KISS1 gene) prevented the formation of metastasis and the spread of cancer inside the cell.

It wasn’t until 10 years later researchers discovered a significant revelation about how the Kisspeptin peptide works.

Kisspeptin is a ligand of the G-protein coupled receptor 54 (GPR54), and many studies published around the middle of the millennium found that it plays a vital role in hypogonadotropic hypogonadism. This facet of the Kisspeptin peptide is still the subject of ongoing study.

Kisspeptin And Reproductive Disorders

Hypogonadism is a frequent hormonal imbalance in which neither the sex organs of the male (the testes) nor the female (the ovaries) generates enough of the corresponding hormones. Hypogonadotropic hypogonadism is a subtype in which low testosterone levels result from hypothalamic or pituitary gland dysfunction.

The release of gonadotropin-releasing hormones from the brain marks the beginning of a typical hormonal cycle (GnRH). Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are secreted from the pituitary gland in response to GnRH (LH). When combined, FSH and LH stimulate the ovaries and testes throughout puberty, producing healthy quantities of estrogen (in females) and sperm (in males).

…